Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Cardiovascular and Renal Benefits of SGLT2 Inhibitors
Lower Treatment Rates of Depression For Some Type 2 Patients
Little Known Benefit in Using SGLT2 Inhibitors
MOST POPULAR ARTICLES OF THE MONTH
#1 Updated Consensus Report on Diabetic Nutrition Therapy
Editor's Note
Many, many times we have had features on the SGLT-2 inhibitors since the first one was introduced in 2013. We have watched as the research has continued, and we have learned that these medications work to lower blood glucose levels, weight and cardiovascular risk. This week we look more at the reasons why this may be happening, and how we can add renal protectivity to the mix.
Onyi Ibeji, PharmD. Candidate, and Amber Satz, PharmD Candidate, both from LECOM School of Pharmacy, are presenting SGLT-2 Inhibitor related articles that focus on the renal issues and how these drugs may correct a problem that often goes untreated in diabetes patients.
Dave Joffe
Editor-in-chief
TOP STORIES -- Diabetes News and Research
The use of SGLT-2 inhibitors produces cardiovascular benefits and reduces the risk of progression of renal impairment in patients with T2DM.
Does being a member of a minority ethnicity put you at risk of being overlooked for depression?
While the major impact of hypomagnesemia on cardiovascular outcomes and T2DM has been known, recent evidence suggests that SGLT2 inhibitors may normalize Mg2+ levels.
About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.